228 related articles for article (PubMed ID: 31455255)
1. Association between serum IgG level and clinical course in primary sclerosing cholangitis.
Hippchen T; Sauer P; Göppert B; Schirmacher P; Gotthardt DN; Weiss KH; Stremmel W; Rupp C
BMC Gastroenterol; 2019 Aug; 19(1):153. PubMed ID: 31455255
[TBL] [Abstract][Full Text] [Related]
2. [Autoimmune liver diseases and their overlap syndromes].
Strassburg CP
Praxis (Bern 1994); 2006 Sep; 95(36):1363-81. PubMed ID: 16989180
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of children and adolescents with primary sclerosing cholangitis and autoimmune sclerosing cholangitis.
Smolka V; Karaskova E; Tkachyk O; Aiglova K; Ehrmann J; Michalkova K; Konecny M; Volejnikova J
Hepatobiliary Pancreat Dis Int; 2016 Aug; 15(4):412-8. PubMed ID: 27498582
[TBL] [Abstract][Full Text] [Related]
4. [Cholestatic liver diseases].
Grimm D; Thimme R
Ther Umsch; 2011 Apr; 68(4):195-9. PubMed ID: 21452140
[TBL] [Abstract][Full Text] [Related]
5. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study.
de Vries EMG; Färkkilä M; Milkiewicz P; Hov JR; Eksteen B; Thorburn D; Chazouillères O; Pares A; Nygård S; Gilja OH; Wunsch E; Invernizzi P; Carbone M; Bernuzzi F; Boberg KM; Røsjø H; Rosenberg W; Beuers UH; Ponsioen CY; Karlsen TH; Vesterhus M
Liver Int; 2017 Oct; 37(10):1554-1561. PubMed ID: 28267887
[TBL] [Abstract][Full Text] [Related]
6. Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis.
Tornai T; Palyu E; Vitalis Z; Tornai I; Tornai D; Antal-Szalmas P; Norman GL; Shums Z; Veres G; Dezsofi A; Par G; Par A; Orosz P; Szalay F; Lakatos PL; Papp M
World J Gastroenterol; 2017 Aug; 23(29):5412-5421. PubMed ID: 28839442
[TBL] [Abstract][Full Text] [Related]
7. Comparative clinical characteristics and natural history of three variants of sclerosing cholangitis: IgG4-related SC, PSC/AIH and PSC alone.
Lian M; Li B; Xiao X; Yang Y; Jiang P; Yan L; Sun C; Zhang J; Wei Y; Li Y; Chen W; Jiang X; Miao Q; Chen X; Qiu D; Sheng L; Hua J; Tang R; Wang Q; Eric Gershwin M; Ma X
Autoimmun Rev; 2017 Aug; 16(8):875-882. PubMed ID: 28564616
[TBL] [Abstract][Full Text] [Related]
8. Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis.
Schulze K; Weismüller TJ; Bubenheim M; Huebener P; Zenouzi R; Lenzen H; Rupp C; Gotthardt D; de Leuw P; Teufel A; Zimmer V; Reiter FP; Rust C; Tharun L; Quaas A; Weidemann SA; Lammert F; Sarrazin C; Manns MP; Lohse AW; Schramm C;
PLoS One; 2015; 10(10):e0140525. PubMed ID: 26489083
[TBL] [Abstract][Full Text] [Related]
9. No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan.
Tanaka A; Tazuma S; Nakazawa T; Isayama H; Tsuyuguchi T; Inui K; Takikawa H
J Hepatobiliary Pancreat Sci; 2017 Apr; 24(4):217-225. PubMed ID: 28103424
[TBL] [Abstract][Full Text] [Related]
10. Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis.
Goet JC; Floreani A; Verhelst X; Cazzagon N; Perini L; Lammers WJ; de Vries AC; van der Meer AJ; van Buuren HR; Hansen BE
J Hepatol; 2019 Nov; 71(5):992-999. PubMed ID: 31278949
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis.
Hartl J; Ehlken H; Sebode M; Peiseler M; Krech T; Zenouzi R; von Felden J; Weiler-Normann C; Schramm C; Lohse AW
J Hepatol; 2018 Apr; 68(4):754-763. PubMed ID: 29180000
[TBL] [Abstract][Full Text] [Related]
12. The management of autoimmunity in patients with cholestatic liver diseases.
Ali AH; Carey EJ; Lindor KD
Expert Rev Gastroenterol Hepatol; 2016; 10(1):73-91. PubMed ID: 26523975
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune Hepatitis, Sclerosing Cholangitis, and Autoimmune Sclerosing Cholangitis or Overlap Syndrome.
Kerkar N; Chan A
Clin Liver Dis; 2018 Nov; 22(4):689-702. PubMed ID: 30266157
[TBL] [Abstract][Full Text] [Related]
14. Clinical analysis of liver transplantation in autoimmune liver diseases.
Zhong CP; Xi ZF; Xia Q
Hepatobiliary Pancreat Dis Int; 2018 Feb; 17(1):27-31. PubMed ID: 29428100
[TBL] [Abstract][Full Text] [Related]
15. Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases.
Rocha HC; Vilela EG
Gastroenterol Hepatol; 2022 Feb; 45(2):83-90. PubMed ID: 34023469
[TBL] [Abstract][Full Text] [Related]
16. Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis.
Nielsen MJ; Thorburn D; Leeming DJ; Hov JR; Nygård S; Moum B; Saffioti F; Gilja OH; Boberg KM; Mazza G; Røsjø H; Pinzani M; Karlsen TH; Karsdal MA; Vesterhus M
Aliment Pharmacol Ther; 2018 Jul; 48(2):179-189. PubMed ID: 29851098
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and management of overlap syndromes.
Bunchorntavakul C; Reddy KR
Clin Liver Dis; 2015 Feb; 19(1):81-97. PubMed ID: 25454298
[TBL] [Abstract][Full Text] [Related]
18. [Autoimmune hepatitis and overlap syndrome: diagnosis].
Berg PA; Klein R
Praxis (Bern 1994); 2002 Aug; 91(34):1339-46. PubMed ID: 12233264
[TBL] [Abstract][Full Text] [Related]
19. Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis.
Bossen L; Vesterhus M; Hov JR; Färkkilä M; Rosenberg WM; Møller HJ; Boberg KM; Karlsen TH; Grønbæk H
Clin Transl Gastroenterol; 2021 Mar; 12(3):e00315. PubMed ID: 33646203
[TBL] [Abstract][Full Text] [Related]
20. [Cholestatic liver diseases].
Thimme R; Opitz OG; Blum HE; Kreisel W
Ther Umsch; 2004 Aug; 61(8):521-7. PubMed ID: 15457969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
